Zhang Yue-Yang, Yang Xiao-Yu, Wan Qin
Department of Endocrinology and Metabolism, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Metabolic Vascular Disease Key Laboratory of Sichuan Province, Luzhou, China.
Front Endocrinol (Lausanne). 2025 Feb 4;16:1537303. doi: 10.3389/fendo.2025.1537303. eCollection 2025.
The Atherogenic Index of Plasma (AIP) was originally developed primarily as a marker for assessing atherosclerosis. Consequently, this study investigates the potential association between AIP and type 2 diabetic complications through a cross-sectional design.
The National Metabolic Management Center(MMC) serves as a comprehensive platform dedicated to the establishment of standardized protocols for the diagnosis, treatment, and long-term follow-up of metabolic diseases. Following the relevant inclusion and exclusion criteria, a total of 3,094 patients were enrolled for subsequent analysis. In this study, logistic regression, restricted cubic splines, and subgroup analyses were employed to evaluate the association between the AIP and four major complications of type 2 diabetes, namely, type 2 diabetes with carotid atherosclerosis (DA), diabetic kidney disease (DKD), diabetic retinopathy (DR), and diabetic peripheral neuropathy (DPN).
The logistic regression results demonstrate that in the fully adjusted model, each SD increase in AIP correlates with an elevated risk of type 2 diabetic kidney disease (DKD), with the risk of kidney damage intensifying alongside higher AIP groupings. The RCS analysis and subgroup analyses similarly revealed a dose-response relationship between AIP levels and the risk of DKD. Furthermore, the AIP was not found to be statistically significantly associated with DA, DR,and DPN.
The AIP may serve as a valuable predictive indicator for evaluating kidney damage in patients with type 2 diabetes, and regular screening of AIP in this population could provide significant benefits in the prevention of DKD.
血浆致动脉粥样硬化指数（AIP）最初主要作为评估动脉粥样硬化的标志物而开发。因此，本研究通过横断面设计调查AIP与2型糖尿病并发症之间的潜在关联。
国家代谢管理中心（MMC）是一个综合平台，致力于建立代谢疾病诊断、治疗和长期随访的标准化方案。根据相关纳入和排除标准，共纳入3094例患者进行后续分析。在本研究中，采用逻辑回归、受限立方样条和亚组分析来评估AIP与2型糖尿病四种主要并发症之间的关联，这四种并发症分别为2型糖尿病合并颈动脉粥样硬化（DA）、糖尿病肾病（DKD）、糖尿病视网膜病变（DR）和糖尿病周围神经病变（DPN）。
逻辑回归结果表明，在完全调整模型中，AIP每增加一个标准差与2型糖尿病肾病（DKD）风险升高相关，随着AIP分组升高，肾脏损害风险加剧。RCS分析和亚组分析同样揭示了AIP水平与DKD风险之间的剂量反应关系。此外，未发现AIP与DA、DR和DPN有统计学显著关联。
AIP可能是评估2型糖尿病患者肾脏损害的有价值预测指标，对该人群定期筛查AIP可能在预防DKD方面带来显著益处。
